Silo Pharma Partners With Global CRO For Central Nervous System Homing Peptide; Shares Move Higher
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has partnered with a global Contract Research Organization (CRO) to study the SPU-16 peptide's ability to target inflamed epithelium in an experimental autoimmune encephalomyelitis (EAE) model, commonly used for multiple sclerosis (MS). This partnership aims to explore the peptide's potential as a targeted drug delivery tool for spinal cord inflammation. Shares of Silo Pharma moved higher following the announcement.
August 07, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's shares moved higher after announcing a partnership with a global CRO to study the SPU-16 peptide's potential in targeting inflamed epithelium in an MS model.
The partnership with a global CRO to study the SPU-16 peptide in an MS model is a significant development for Silo Pharma. The positive market reaction, as evidenced by the share price increase, indicates investor confidence in the potential of this research to lead to effective treatments for MS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100